MAPT and Cognitive impairment: Targeting regions with classic tau pathology, such as the hippocampus, for FUS BBB opening in patients with cognitive impairment may enhance the diagnostic sensitivity of pTau-181 and other neurodegeneration biomarkers, as demonstrated in animal studies.25